A unique strategy of frugal excellence and bold foresight have made AmerisourceBergen, a $100 billion Chesterbrook drug distributor, a shining star — so far — on Wall Street.
Led by a pioneering CEO who rose through the company ranks and exemplified its longstanding penny-watching culture, AmerisourceBergen made a key 2013 investment with Walgreens that this year has netted 35% growth in annual revenue and a 21 to 23% increase in adjusted diluted earnings per share, according to an Investor’s Business Daily report.
“His command of the company’s fundamentals is extremely strong,” analyst Steven Halper said of CEO Steven Collis in the article. “And he’s got the appropriate level of long-term insight. … If you asked me five years ago if they could do a deal like that, I’d have said no.”
Read more about the deal and AmerisourceBergen’s early success in the Investor’s Business Daily here.
_______
Top image courtesy of philly.com.
